Suppr超能文献

表达赖氨酰氧化酶样蛋白 4 的中性粒细胞存在于对抗血管生成治疗有抵抗的结直肠癌肝转移中。

Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy.

机构信息

Department of Medicine, McGill University, Montreal, Canada.

Research Institute of the McGill University Health Centre, Montreal, Canada.

出版信息

J Pathol. 2020 Jun;251(2):213-223. doi: 10.1002/path.5449. Epub 2020 May 18.

Abstract

Colorectal cancer liver metastases (CRCLM) that present with a replacement histopathological growth pattern (HGP) are resistant to neoadjuvant anti-angiogenic therapy. Surrogate biomarkers are not available to preoperatively identify patients with these tumors. Here we identify differentially expressed genes between CRCLM with a replacement HGP and those with a desmoplastic HGP using RNA sequencing. We demonstrate that LOXL4 is transcriptionally upregulated in replacement HGP CRCLM compared with desmoplastic HGP CRCLM and the adjacent normal liver. Interestingly, lysyl oxidase-like 4 (LOXL4) protein was expressed by neutrophils present in the tumor microenvironment in replacement HGP CRCLM. We further demonstrate that LOXL4 expression is higher in circulating neutrophils of cancer patients compared with healthy control patients and its expression can be induced by stimulation with lipopolysaccharide and TNF-α. Our study is the first to show the expression of LOXL4 in neutrophils and reveals the potential for LOXL4-expressing neutrophils to support the replacement HGP phenotype and to serve as a surrogate biomarker for this subtype of CRCLM. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

摘要

结直肠癌肝转移(CRCLM)中存在替代组织病理学生长模式(HGP)的患者对新辅助抗血管生成治疗具有耐药性。目前尚无可用于术前识别这些肿瘤患者的替代生物标志物。在这里,我们使用 RNA 测序来确定具有替代 HGP 的 CRCLM 与具有纤维母细胞性 HGP 的 CRCLM 之间差异表达的基因。我们证明与纤维母细胞性 HGP 的 CRCLM 相比,LOXL4 在替代 HGP 的 CRCLM 中转录上调。有趣的是,在替代 HGP 的 CRCLM 中,LOXL4 蛋白由肿瘤微环境中的中性粒细胞表达。我们进一步证明,与健康对照组患者相比,癌症患者循环中的中性粒细胞中 LOXL4 的表达更高,并且其表达可以通过脂多糖和 TNF-α的刺激来诱导。我们的研究首次表明 LOXL4 在中性粒细胞中的表达,并揭示了 LOXL4 表达的中性粒细胞支持替代 HGP 表型的潜力,并可作为这种 CRCLM 亚型的替代生物标志物。 ©2020 大不列颠及爱尔兰病理学学会。由 John Wiley & Sons,Ltd. 出版。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验